Sign in
4

Changes in Ownership

Lexeo Therapeutics, Inc. Filed Acc 0001415889-25-022468

Chief Development Officer sold 382 shares at $4.67 ($1,783)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
See Tai Sandi Chief Development Officer 2025-08-18 Sale −382 $4.67 $1,783 58,860 D: show line 1 in the form
Open-market sales · 382 sh · avg $4.67 · $1,783
Loading xslF345X05/form4-08202025_080818.xml…